Valentina Boni, MD, PhD, Talks Safety of Lurbinectedin Monotherapy in Pretreated BRCA-Associated Advanced Breast Cancer

Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about lurbinectedin (Zepzelca) monotherapy for patients with BRCA1/2-associated metastatic breast cancer, which was examined in a phase 2 basket study (NCT02454972). Boni reviewed the safety profile and future promise of this treatment strategy.

Read the full article, and watch the interview at